Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow-to-Debt Ratio
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow-to-Debt Ratio of 0.23x as of December 2025, meaning its operating cash flow of ₩87.00 Billion could theoretically repay 0% of its total liabilities (₩372.04 Billion) in one year. Check 326030 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sk Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Sk Biopharmaceuticals Co Ltd across 10 annual periods. Also explore 326030 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sk Biopharmaceuticals Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Sk Biopharmaceuticals Co Ltd. For market capitalisation and broader financial context, see market value of Sk Biopharmaceuticals Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.47x | ₩176.33 Billion | ₩372.04 Billion | ▲ +131.2% |
| 2024 | 0.21x | ₩94.90 Billion | ₩462.83 Billion | ▲ +187.5% |
| 2023 | -0.23x | ₩-94.20 Billion | ₩402.22 Billion | ▲ +49.1% |
| 2022 | -0.46x | ₩-159.92 Billion | ₩347.68 Billion | ▲ +1.2% |
| 2021 | -0.47x | ₩-92.87 Billion | ₩199.46 Billion | ▲ +73.2% |
| 2020 | -1.74x | ₩-210.73 Billion | ₩121.17 Billion | ▼ -225.2% |
| 2019 | -0.53x | ₩-81.33 Billion | ₩152.10 Billion | ▲ +86.0% |
| 2018 | -3.83x | ₩-141.28 Billion | ₩36.91 Billion | ▼ -99.0% |
| 2017 | -1.92x | ₩-98.34 Billion | ₩51.12 Billion | ▼ -81.6% |
| 2016 | -1.06x | ₩-48.94 Billion | ₩46.21 Billion | — |